Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0TA0L
|
||||
Former ID |
DNC005388
|
||||
Drug Name |
FR-181157
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [541163] | ||
Structure |
Download2D MOL |
||||
Formula |
C30H27NO4
|
||||
InChI |
InChI=1S/C30H27NO4/c32-27(33)20-34-25-16-9-10-21(19-25)18-24-15-7-8-17-26(24)30-31-28(22-11-3-1-4-12-22)29(35-30)23-13-5-2-6-14-23/h1-6,9-14,16-17,19,24H,7-8,15,18,20H2,(H,32,33)
|
||||
InChIKey |
QVZSFHJAGXKMMQ-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Prostaglandin E2 receptor, EP4 subtype | Target Info | Inhibitor | [527530] | |
Prostaglandin E2 receptor EP3 subtype | Target Info | Inhibitor | [527579] | ||
Prostacyclin receptor | Target Info | Inhibitor | [528308] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Inflammatory mediator regulation of TRP channels | |||||
Renin secretion | |||||
Pathways in cancerhsa04020:Calcium signaling pathway | |||||
cAMP signaling pathway | |||||
Regulation of lipolysis in adipocytes | |||||
Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction | |||||
Vascular smooth muscle contraction | |||||
Platelet activation | |||||
Pathway Interaction Database | Thromboxane A2 receptor signaling | ||||
References | |||||
Ref 527530 | J Med Chem. 2005 May 5;48(9):3103-6.Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. | ||||
Ref 527579 | Bioorg Med Chem Lett. 2005 Jul 1;15(13):3284-7.Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. | ||||
Ref 528308 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4861-4. Epub 2006 Jul 11.Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.